
  
    
      
        Background_NNP
        Prolonged_NNP or_CC repeated_VBN agonist_NN stimulation_NN of_IN G_NNP
        protein-coupled_JJ receptors_NNS frequently_RB causes_VBZ a_DT reduction_NN in_IN
        the_DT response_NN to_TO the_DT agonist_NN [_NN 1_CD ]_NN ._. Short-term_JJ agonist_NN
        exposure_NN results_NNS in_IN desensitization_NN that_WDT is_VBZ characterized_VBN
        by_IN a_DT rapid_JJ (_( minutes_NNS )_) and_CC reversible_JJ uncoupling_VBG of_IN the_DT
        receptor_NN from_IN the_DT G_NNP protein_NN followed_VBN by_IN sequestration_NN
        and_CC /_NN or_CC internalization_NN of_IN receptors_NNS from_IN the_DT cell_NN surface_NN ._.
        Down-regulation_NNP occurs_VBZ after_IN prolonged_JJ agonist_NN treatment_NN
        (_( hours_NNS to_TO days_NNS )_) ,_, resulting_VBG in_IN a_DT loss_NN of_IN receptor_NN binding_JJ
        sites_NNS [_NN 2_CD 3_CD 4_CD ]_NN ._. The_DT processes_VBZ involved_VBN in_IN homologous_RB
        desensitization_NN have_VBP been_VBN extensively_RB investigated_VBN for_IN the_DT
        beta-_NN 2_CD adrenergic_JJ receptor_NN ,_, which_WDT is_VBZ the_DT prototypical_JJ G_NNP
        protein-coupled_JJ receptor_NN ._. Initial_JJ uncoupling_VBG of_IN the_DT beta-_NN 2_CD
        receptor_NN from_IN the_DT G_NNP protein_NN after_IN agonist_NN binding_JJ is_VBZ
        mediated_JJ by_IN phosphorylation_NN by_IN G_NNP protein-coupled_JJ receptor_NN
        kinase_NN (_( GRK_NNP )_) of_IN specific_JJ residues_NNS in_IN the_DT carboxyl_NN tail_NN of_IN
        the_DT receptor_NN ._. The_DT phosphorylated_JJ beta-_NN 2_CD receptor_NN enhances_VBZ
        the_DT binding_JJ of_IN beta-arrestin_JJ ,_, which_WDT not_RB only_RB uncouples_NNS the_DT
        receptor_NN from_IN the_DT signal_NN transduction_NN process_NN but_CC also_RB
        serves_VBZ as_IN an_DT adapter_NN protein_NN that_IN mediates_NNS entry_NN into_IN the_DT
        internalization_NN pathway_NN [_NN 5_CD ]_NN ,_, as_RB well_RB as_RB serving_VBG as_IN a_DT
        platform_NN for_IN additional_JJ signaling_VBG pathways_NNS [_NN 6_CD ]_NN ._. The_DT
        mechanisms_NNS of_IN beta-_NN 2_CD adrenergic_JJ receptor_NN down-regulation_JJ
        appear_VB to_TO involve_VB both_DT an_DT increase_NN in_IN the_DT rate_NN of_IN
        degradation_NN of_IN the_DT receptor_NN as_RB well_RB as_IN a_DT decrease_NN in_IN the_DT
        levels_NNS of_IN beta_NN receptor_NN mRNA_NN [_NN 7_CD ]_NN ._. Down-regulation_NNP of_IN the_DT
        beta-_NN 2_CD receptor_NN is_VBZ ,_, in_IN part_NN ,_, due_JJ to_TO trafficking_NN of_IN the_DT
        beta-_NN 2_CD receptor_NN to_TO lysosomes_NNS via_IN the_DT clathrin-coated_JJ pit_NN
        endosomal_NN pathway_NN [_NN 8_CD 9_CD ]_NN ._.
        The_DT alpha-_NN 2_CD adrenergic_JJ receptors_NNS also_RB undergo_VBP
        agonist-induced_JJ desensitization_NN and_CC down-regulation_JJ ._.
        Desensitization_NNP occurs_VBZ both_DT in_IN cell_NN culture_NN systems_NNS [_NN 10_CD 11_CD
        12_CD ]_NN and_CC in_IN the_DT intact_JJ animal_NN [_NN 13_CD 14_CD ]_NN ._. In_IN general_JJ the_DT
        mechanisms_NNS of_IN desensitization_NN for_IN the_DT alpha-_NN 2_CD adrenergic_JJ
        receptors_NNS appear_VBP to_TO be_VB similar_JJ to_TO those_DT for_IN the_DT beta-_NN 2_CD
        receptor_NN ._. There_EX are_VBP three_CD subtypes_NNS of_IN the_DT alpha-_NN 2_CD
        adrenergic_JJ receptor_NN :_: alpha-_NN 2_CD A_DT ;_: alpha-_NN 2_CD B_NNP ;_: and_CC alpha-_NN 2_CD C_NNP [_NN 15_CD
        ]_NN ._. The_DT human_JJ alpha-_NN 2_CD A_DT subtype_NN undergoes_NNS phosphorylation_NN
        and_CC short-term_JJ desensitization_NN [_NN 11_CD 12_CD ]_NN ,_, whereas_IN the_DT
        human_JJ alpha-_NN 2_CD C_NNP subtype_NN is_VBZ not_RB phosphorylated_JJ [_NN 16_CD ]_NN and_CC
        does_VBZ not_RB desensitize_NN [_NN 11_CD ]_NN ._. The_DT human_JJ alpha-_NN 2_CD C_NNP subtype_NN ,_,
        however_RB ,_, does_VBZ undergo_VB arrestin-dependent_JJ internalization_NN [_NN
        17_CD ]_NN ._. Many_JJ studies_NNS [_NN 11_CD 18_CD ]_NN ,_, including_VBG those_DT from_IN our_PRP$
        laboratory_NN [_NN 10_CD 19_CD 20_CD ]_NN ,_, have_VBP demonstrated_VBN agonist-induced_JJ
        down-regulation_JJ of_IN alpha-_NN 2_CD receptors_NNS ,_, although_IN much_RB less_JJR is_VBZ
        known_VBN about_IN the_DT specific_JJ mechanisms_NNS for_IN down-regulation_JJ as_IN
        compared_VBN to_TO the_DT beta-_NN 2_CD receptor_NN ._. In_IN contrast_NN to_TO alpha-_NN 2_CD A_DT
        and_CC alpha-_NN 2_CD B_NNP adrenergic_JJ receptors_NNS from_IN several_JJ species_NNS ,_, the_DT
        human_JJ alpha-_NN 2_CD C_NNP receptor_NN does_VBZ not_RB appear_VB to_TO down-regulate_JJ in_IN
        response_NN to_TO agonist_NN treatment_NN in_IN transfected_JJ cell_NN culture_NN
        systems_NNS [_NN 11_CD ]_NN ._. By_IN contrast_NN ,_, the_DT opossum_NN alpha-_NN 2_CD C_NNP receptor_NN
        in_IN the_DT OK_JJ cell_NN line_NN does_VBZ down-regulate_JJ in_IN response_NN to_TO
        norepinephrine_NN [_NN 19_CD 20_CD ]_NN ._. The_DT reason_NN for_IN this_DT difference_NN
        is_VBZ the_DT focus_NN of_IN the_DT current_JJ studies_NNS ._.
        The_DT human_JJ alpha-_NN 2_CD A_DT adrenergic_JJ receptor_NN has_VBZ an_DT acidic_JJ
        serine-rich_JJ motif_NN (_( EESSSSD_NNP )_) in_IN the_DT third_JJ intracellular_NN loop_NN
        that_WDT has_VBZ been_VBN shown_VBN to_TO be_VB important_JJ in_IN agonist-induced_JJ
        desensitization_NN but_CC not_RB in_IN agonist-induced_JJ
        sequestration_NN /_NN internalization_NN ._. Site-directed_NNP mutagenesis_NNS
        studies_NNS indicate_VBP that_IN all_DT four_CD of_IN these_DT serines_NNS are_VBP
        phosphorylated_JJ by_IN GRK_NNP ,_, and_CC all_DT four_CD are_VBP needed_VBN for_IN
        desensitization_NN [_NN 12_CD ]_NN ._. The_DT influence_NN of_IN this_DT motif_NN on_IN
        down-regulation_JJ was_VBD not_RB investigated_VBN ,_, however_RB ._. The_DT opossum_NN
        alpha-_NN 2_CD C_NNP adrenergic_JJ receptor_NN has_VBZ a_DT very_RB similar_JJ acidic_JJ
        serine_NN motif_NN (_( EESSTSE_NNP )_) in_IN the_DT third_JJ intracellular_NN loop_NN
        (_( Figure_NN 1_CD ;_: [_NN 21_CD ]_NN )_) ,_, whereas_IN the_DT human_JJ alpha-_NN 2_CD C_NNP receptor_NN
        has_VBZ a_DT DESSAAAE_NNP sequence_NN in_IN the_DT same_JJ region_NN (_( Figure_NN 2_CD ;_: [_NN 22_CD
        ]_NN )_) ._. Thus_RB ,_, we_PRP postulated_JJ that_IN the_DT lack_NN of_IN down-regulation_JJ
        in_IN the_DT human_JJ alpha-_NN 2_CD C_NNP was_VBD related_VBN to_TO having_VBG only_RB two_CD rather_RB
        than_IN four_CD serines_NNS in_IN the_DT motif_NN ,_, and_CC furthermore_RB that_IN the_DT
        ability_NN of_IN the_DT opossum_NN alpha-_NN 2_CD C_NNP to_TO undergo_VB down-regulation_JJ
        was_VBD dependent_JJ on_IN having_VBG all_DT four_CD serine_NN /_NN threonine_NN residues_NNS
        in_IN the_DT EESSTSE_NNP motif_NN ._. To_TO test_VB this_DT hypothesis_NNS ,_, we_PRP mutated_VBN
        the_DT opossum_NN alpha-_NN 2_CD C_NNP serines_NNS and_CC threonine_NN residues_NNS to_TO
        alanines_NNS and_CC valine_NN ,_, respectively_RB ,_, and_CC tested_VBD whether_IN the_DT
        expressed_VBN receptors_NNS would_MD down-regulate_JJ ._. Down-regulation_NNP
        was_VBD not_RB observed_VBN in_IN the_DT mutated_VBN receptors_NNS following_VBG
        treatment_NN with_IN norepinephrine_NN for_IN 24_CD h_NN ._.
      
      
        Results_NNS
        
          Sequence_NNP of_IN the_DT opossum_NN alpha-_NN 2_CD C_NNP adrenergic_JJ
          receptor_NN
          In_IN the_DT process_NN of_IN confirming_VBG the_DT mutations_NNS ,_, we_PRP also_RB
          completely_RB re-sequenced_JJ the_DT wild-type_JJ clone_NN and_CC found_VBD
          several_JJ differences_NNS from_IN the_DT originally_RB published_VBN
          sequence_NN (_( GenBank_NNP #_# U_NNP 04310_CD [_NN 21_CD ]_NN )_) ._. The_DT corrected_VBN
          sequence_NN differs_VBZ from_IN the_DT original_NN in_IN 19_CD bases_NNS ,_, which_WDT
          results_VBZ in_IN 11_CD amino_JJ acid_NN residue_NN changes_NNS as_IN detailed_JJ in_IN
          Figure_NN 2_CD ._. The_DT sequence_NN has_VBZ been_VBN corrected_VBN in_IN Genbank_NNP ._.
        
        
          Characterization_NNP of_IN mutated_VBN receptors_NNS
          The_DT results_NNS of_IN [_NN 3_CD H_NNP ]_NN rauwolscine_NN saturation_NN experiments_NNS
          using_VBG the_DT wild-type_JJ and_CC mutated_VBN receptors_NNS from_IN two_CD
          independent_JJ transfections_NNS of_IN both_DT mutations_NNS are_VBP given_VBN in_IN
          Table_NNP 1_CD ._. The_DT K_NNP 
          d_SYM values_NNS for_IN the_DT two_CD mutants_NNS
          (_( 0_CD ._. 071_CD -_: 0_CD ._. 118_CD nM_NN )_) were_VBD similar_JJ to_TO those_DT of_IN the_DT wild-type_JJ
          (_( 0_CD ._. 113_CD nM_NN )_) and_CC similar_JJ to_TO the_DT previously_RB reported_VBN K_NNP 
          d_SYM of_IN 0_CD ._. 056_CD nM_NN for_IN the_DT wild-type_JJ
          alpha-_NN 2_CD receptor_NN for_IN [_NN 3_CD H_NNP ]_NN rauwolscine_NN in_IN NaPO_NNP 
          4_CD buffer_NN [_NN 23_CD ]_NN ._. Inhibition_NNP
          experiments_NNS with_IN [_NN 3_CD H_NNP ]_NN rauwolscine_NN indicated_VBD that_IN the_DT
          affinity_NN of_IN norepinephrine_NN for_IN the_DT mutated_VBN receptors_NNS was_VBD
          approximately_RB two-fold_JJ higher_JJR (_( lower_JJR K_NNP 
          d_SYM value_NN )_) than_IN for_IN wild-type_JJ receptor_NN
          (_( Figure_NN 3_LS )_) ._.
        
        
          Down-regulation_NNP
          After_IN a_DT 24_CD h_NN treatment_NN with_IN 0_CD ._. 3_CD μM_NN norepinephrine_NN ,_, the_DT
          wild-type_JJ receptor_NN down-regulated_JJ to_TO 65_CD ±_NN 10_CD %_NN of_IN control_NN
          (_( p_NN <_NN 0_CD ._. 05_CD ;_: n_NN =_SYM 7_CD )_) ._. By_IN contrast_NN ,_, no_DT down-regulation_JJ was_VBD
          observed_VBN with_IN either_DT the_DT SSVA_NNP (_( 114_CD ±_NN 10_CD %_NN of_IN control_NN )_) or_CC
          the_DT AAVA_NNP (_( 110_CD ±_NN 9_CD %_NN of_IN control_NN )_) receptors_NNS (_( Figure_NN 4_LS )_) ._.
        
      
      
        Discussion_NNP
        All_DT three_CD alpha-_NN 2_CD adrenergic_JJ receptor_NN subtypes_NNS from_IN
        nearly_RB all_DT species_NNS that_WDT have_VBP been_VBN tested_VBN undergo_VBP
        agonist-induced_JJ down-regulation_JJ [_NN 24_CD 25_CD ]_NN ._. Interestingly_RB ,_,
        we_PRP have_VBP shown_VBN that_IN the_DT potency_NN of_IN norepinephrine_NN to_TO produce_VB
        down-regulation_JJ differs_VBZ among_IN alpha-_NN 2_CD receptor_NN subtypes_NNS [_NN
        19_CD 24_CD ]_NN ._. The_DT concentration_NN of_IN norepinephrine_NN required_VBN to_TO
        produce_VB half-maximal_JJ down-regulation_JJ is_VBZ approximately_RB 2_CD μM_NN
        for_IN the_DT alpha-_NN 2_CD A_DT receptor_NN ._. In_IN contrast_NN ,_, norepinephrine_NN is_VBZ
        more_RBR potent_JJ at_IN down-regulating_JJ the_DT alpha-_NN 2_CD B_NNP and_CC alpha-_NN 2_CD C_NNP
        subtypes_NNS ,_, with_IN a_DT concentration_NN of_IN only_RB 70_CD nM_NN required_VBN to_TO
        produce_VB half-maximal_JJ down-regulation_JJ ._. This_DT difference_NN in_IN
        potency_NN appears_VBZ to_TO be_VB a_DT characteristic_NN of_IN the_DT receptor_NN
        protein_NN itself_PRP ,_, because_IN the_DT cellular_JJ environment_NN in_IN which_WDT a_DT
        particular_JJ subtype_NN is_VBZ expressed_VBN does_VBZ not_RB affect_VB the_DT potency_NN
        of_IN norepinephrine_NN to_TO produce_VB down-regulation_JJ ._.
        The_DT human_JJ alpha-_NN 2_CD C_NNP receptor_NN is_VBZ somewhat_RB unique_JJ among_IN the_DT
        alpha-_NN 2_CD receptors_NNS in_IN that_IN it_PRP does_VBZ not_RB appear_VB to_TO undergo_VB
        agonist-induced_JJ down-regulation_JJ [_NN 11_CD ]_NN ._. The_DT human_JJ alpha-_NN 2_CD A_DT
        adrenergic_JJ receptor_NN ,_, which_WDT does_VBZ undergo_VB down-regulation_JJ ,_,
        has_VBZ an_DT acidic_JJ serine_NN motif_NN (_( EESSSSD_NNP )_) in_IN the_DT third_JJ
        intracellular_NN loop_NN ._. Sequentially_NNP mutating_VBG each_DT of_IN the_DT four_CD
        serines_NNS to_TO alanine_NN decreased_VBD the_DT phosphorylation_NN of_IN the_DT
        receptor_NN by_IN approximately_RB 25_CD %_NN for_IN each_DT serine_NN ,_, and_CC mutating_VBG
        either_CC the_DT first_JJ two_CD or_CC the_DT last_JJ two_CD serines_NNS to_TO alanines_NNS
        prevented_VBD agonist-induced_JJ desensitization_NN ,_, but_CC not_RB
        agonist-induced_JJ sequestration_NN /_NN internalization_NN [_NN 12_CD ]_NN ._. The_DT
        influence_NN of_IN mutations_NNS in_IN this_DT motif_NN on_IN down-regulation_JJ has_VBZ
        not_RB been_VBN investigated_VBN ._. The_DT human_JJ alpha-_NN 2_CD C_NNP receptor_NN ,_, by_IN
        contrast_NN ,_, has_VBZ a_DT DESSAAAE_NNP sequence_NN in_IN the_DT same_JJ region_NN
        [_NN Figure_NN 2_CD ;_: [_NN 22_CD ]_NN ]_NN ._. Thus_RB ,_, it_PRP is_VBZ possible_JJ that_IN the_DT lack_NN of_IN
        desensitization_NN and_CC perhaps_RB also_RB down-regulation_JJ of_IN the_DT
        human_JJ alpha-_NN 2_CD C_NNP receptor_NN is_VBZ due_JJ to_TO the_DT fact_NN that_IN there_EX are_VBP
        only_RB two_CD hydroxyl_NN residues_NNS in_IN the_DT DESSAAAE_NNP motif_NN rather_RB
        than_IN the_DT four_CD hydroxyl_NN residues_NNS in_IN the_DT alpha-_NN 2_CD A_DT EESSSSD_NNP
        motif_NN ._.
        The_DT opossum_NN alpha-_NN 2_CD C_NNP adrenergic_JJ receptor_NN has_VBZ a_DT EESSTSE_NNP
        acidic_JJ serine_NN /_NN threonine_NN motif_NN in_IN the_DT third_JJ intracellular_NN
        loop_NN (_( Figures_NNS 1_CD and_CC 2_LS )_) ,_, which_WDT could_MD be_VB a_DT substrate_NN for_IN GRK_NNP
        based_VBN on_IN the_DT EESSSSD_NNP motif_NN of_IN the_DT alpha-_NN 2_CD A_DT subtype_NN ._. Thus_RB ,_,
        we_PRP postulated_JJ that_IN the_DT lack_NN of_IN down-regulation_JJ in_IN the_DT human_JJ
        alpha-_NN 2_CD C_NNP subtype_NN is_VBZ related_VBN to_TO having_VBG only_RB two_CD rather_RB than_IN
        four_CD serines_NNS in_IN the_DT motif_NN ,_, and_CC that_IN mutating_VBG the_DT threonine_NN
        and_CC serine_NN residues_NNS at_IN the_DT end_NN of_IN the_DT opossum_NN EESSTSE_NNP motif_NN
        to_TO valine_NN and_CC alanine_NN residues_NNS to_TO give_VB EESSVAE_NNP might_MD
        prevent_VB down-regulation_JJ of_IN the_DT opossum_NN alpha-_NN 2_CD C_NNP receptor_NN ._.
        Consistent_NNP with_IN this_DT prediction_NN ,_, treatment_NN with_IN 0_CD ._. 3_CD μM_NN
        norepinephrine_NN for_IN 24_CD h_NN failed_VBD to_TO down-regulate_JJ the_DT
        receptor_NN containing_VBG the_DT motif_NN mutated_VBN to_TO EESSVAE_NNP ,_, although_IN
        the_DT wild-type_JJ receptor_NN with_IN the_DT EESSTSE_NNP motif_NN was_VBD
        down-regulated_JJ by_IN 35_CD %_NN ._.
        The_DT inhibition_NN data_NN indicate_VBP that_IN the_DT affinity_NN of_IN
        norepinephrine_NN for_IN the_DT receptors_NNS containing_VBG the_DT mutations_NNS
        is_VBZ slightly_RB higher_JJR than_IN for_IN the_DT wild-type_JJ ._. The_DT affinity_NN of_IN
        norepinephrine_NN for_IN the_DT mutated_VBN receptor_NN lacking_VBG two_CD of_IN the_DT
        hydroxyl_NN residues_NNS was_VBD approximately_RB twice_RB as_RB high_JJ as_IN the_DT
        wild-type_JJ ._. The_DT elimination_NN of_IN the_DT remaining_VBG two_CD hydroxyl_NN
        residues_NNS did_VBD not_RB have_VB any_DT additional_JJ effect_NN on_IN the_DT affinity_NN
        of_IN norepinephrine_NN ._. These_DT data_NNS eliminate_VBP the_DT possibility_NN
        that_IN the_DT lack_NN of_IN down-regulation_JJ in_IN cells_NNS containing_VBG the_DT
        mutated_VBN receptors_NNS is_VBZ a_DT consequence_NN of_IN the_DT mutants_NNS having_VBG a_DT
        lower_JJR affinity_NN for_IN norepinephrine_NN than_IN the_DT wild-type_JJ ._.
        The_DT elimination_NN of_IN the_DT terminal_NN two_CD hydroxyl_NN amino_JJ acid_NN
        residues_NNS in_IN the_DT EESSTSE_NNP motif_NN is_VBZ sufficient_JJ to_TO prevent_VB
        down-regulation_JJ of_IN the_DT opossum_NN alpha-_NN 2_CD C_NNP adrenergic_JJ
        receptor_NN ._. Similarly_RB ,_, mutation_NN of_IN only_RB two_CD serine_NN residues_NNS
        in_IN the_DT human_JJ alpha-_NN 2_CD A_DT receptor_NN resulted_VBD in_IN a_DT loss_NN of_IN
        desensitization_NN [_NN 12_CD ]_NN ._. Because_IN the_DT EESSSSE_NNP motif_NN in_IN the_DT
        human_JJ alpha-_NN 2_CD A_DT receptor_NN is_VBZ a_DT known_VBN GRK_NNP substrate_NN ,_, and_CC
        because_IN eliminating_VBG two_CD potential_JJ phosphorylation_NN sites_NNS
        prevents_VBZ down-reguation_JJ ,_, phosphorylation_NN of_IN the_DT opossum_NN
        alpha-_NN 2_CD C_NNP receptor_NN may_MD be_VB important_JJ in_IN the_DT mechanism_NN of_IN
        down-regulation_JJ of_IN this_DT receptor_NN ._. By_IN contrast_NN ,_, a_DT deletion_NN
        of_IN twelve_CD residues_NNS of_IN the_DT human_JJ alpha-_NN 2_CD A_DT receptor_NN (_( 293_CD -_: 304_CD )_)
        which_WDT includes_VBZ the_DT EESSSSE_NNP motif_NN did_VBD not_RB appear_VB to_TO prevent_VB
        agonist-induced_JJ down-regulation_JJ [_NN 26_CD ]_NN ._. Thus_RB a_DT
        phosphorylation_NN pathway_NN may_MD not_RB be_VB involved_VBN in_IN
        agonist-induced_JJ down-regulation_JJ of_IN the_DT alpha-_NN 2_CD A_DT adrenergic_JJ
        receptor_NN ._.
        In_IN addition_NN to_TO the_DT hydroxyl_NN amino_JJ acid_NN residues_NNS ,_, acidic_JJ
        residues_NNS may_MD also_RB be_VB an_DT important_JJ sequence_NN element_NN for_IN
        alpha-_NN 2_CD adrenergic_JJ receptor_NN phosphorylation_NN and_CC regulation_NN
        [_NN 27_CD 28_CD ]_NN ._. The_DT region_NN from_IN 300_CD to_TO 313_CD in_IN the_DT opossum_NN
        alpha-_NN 2_CD C_NNP receptor_NN ,_, which_WDT encompasses_VBZ the_DT EESSTSE_NNP motif_NN ,_, is_VBZ
        a_DT high_JJ acidic_JJ region_NN ,_, with_IN 50_CD %_NN (_( seven_CD of_IN fourteen_CD )_) of_IN the_DT
        residues_NNS being_VBG acidic_JJ amino_JJ acids_NNS (_( Figure_NN 2_LS )_) ._. In_IN an_DT effort_NN
        to_TO determine_VB if_IN four_CD hydroxyl_NN amino_JJ acid_NN residues_NNS in_IN an_DT
        acidic_JJ environment_NN might_MD be_VB a_DT common_JJ motif_NN for_IN
        phosphorylation_NN and_CC receptor_NN regulation_NN ,_, we_PRP searched_VBD the_DT G_NNP
        Protein-_NNP Coupled_VBN Receptor_NNP Database_NNP for_IN four_CD consecutive_JJ
        hydroxyl_NN residues_NNS (_( either_CC serine_NN or_CC threonine_NN )_) in_IN a_DT linear_JJ
        sequence_NN that_WDT was_VBD at_IN least_JJS 1_CD /_NN 3_CD acidic_JJ with_IN no_DT basic_JJ
        residues_NNS which_WDT occurred_VBD in_IN either_DT the_DT third_JJ intracellular_NN
        loop_NN or_CC the_DT carboxyl_NN terminal_NN tail_NN ._. As_IN can_MD be_VB seen_VBN from_IN the_DT
        results_NNS in_IN Table_NNP 3_CD ,_, this_DT does_VBZ not_RB appear_VB to_TO be_VB a_DT common_JJ
        motif_NN for_IN G_NNP protein-coupled_JJ receptors_NNS ,_, not_RB even_RB for_IN alpha-_NN 2_CD
        adrenergic_JJ receptors_NNS ._. Indeed_RB ,_, this_DT motif_NN is_VBZ not_RB found_VBN in_IN
        the_DT alpha-_NN 2_CD B_NNP subtype_NN which_WDT does_VBZ undergo_VB agonist-induced_JJ
        down-regulation_JJ ,_, although_IN as_IN noted_VBN above_IN a_DT highly_RB acidic_JJ
        region_NN appears_VBZ to_TO be_VB important_JJ and_CC could_MD be_VB related_VBN to_TO the_DT
        additional_JJ negative_JJ charge_NN provided_VBN by_IN phosphorylation_NN ._.
        Thus_RB ,_, it_PRP is_VBZ likely_JJ that_IN there_EX are_VBP multiple_JJ mechanisms_NNS that_WDT
        are_VBP involved_VBN in_IN down-regulation_JJ of_IN G_NNP protein-coupled_JJ
        receptors_NNS ._.
      
      
        Conclusions_NNP
        A_DT motif_NN with_IN four_CD hydroxyl_NN amino_JJ acid_NN residues_NNS in_IN an_DT
        acidic_JJ environment_NN appears_VBZ to_TO be_VB important_JJ for_IN
        down-regulation_JJ of_IN the_DT alpha-_NN 2_CD C_NNP adrenergic_JJ receptor_NN ._. The_DT
        human_JJ alpha-_NN 2_CD C_NNP receptor_NN ,_, which_WDT has_VBZ a_DT DESSAAAE_NNP motif_NN with_IN
        only_RB two_CD hydroxyl_NN residues_NNS ,_, does_VBZ not_RB undergo_VB
        down-regulation_JJ ._. Modification_NNP of_IN the_DT EESSTSE_NNP to_TO EESSVAE_NNP was_VBD
        sufficient_JJ to_TO prevent_VB down-regulation_JJ of_IN the_DT opossum_NN
        alpha-_NN 2_CD C_NNP adrenergic_JJ receptor_NN ._. Because_IN these_DT are_VBP potential_JJ
        GRK_NNP phosphorylation_NN sites_NNS ,_, our_PRP$ data_NNS further_JJ suggest_VBP that_IN
        GRK_NNP phosphorylation_NN may_MD be_VB involved_VBN in_IN down-regulation_JJ of_IN
        the_DT alpha-_NN 2_CD C_NNP adrenergic_JJ receptor_NN ._.
      
      
        Materials_NNS and_CC Methods_NNP
        
          Materials_NNS
          Restriction_NNP enzymes_NNS were_VBD purchased_VBN from_IN New_NNP England_NNP
          Biolabs_NNP (_( Boston_NNP ,_, MA_NNP )_) ._. Norepinephrine_NNP and_CC other_JJ chemicals_NNS
          were_VBD from_IN Sigma_NNP (_( St_NNP ._. Louis_NNP ,_, MO_NNP )_) ._.
        
        
          Site-directed_NNP mutagenesis_NNS
          Mutations_NNP of_IN the_DT opossum_NN alpha-_NN 2_CD C_NNP adrenergic_JJ receptor_NN
          cDNA_NN in_IN pRc_NN /_NN CMV_NNP vector_NN described_VBD previously_RB [_NN 21_CD ]_NN was_VBD
          accomplished_VBN using_VBG the_DT QuickChange_NNP ™_NN Site_NNP Directed_NNP
          Mutagenesis_NNP Kit_NNP (_( Stratagene_NNP ,_, LaJolla_NNP ,_, CA_NNP )_) ._. The_DT SSTS_NNP
          sequence_NN in_IN the_DT third_JJ cytoplasmic_JJ loop_NN (_( amino_JJ acid_NN
          residues_NNS 309_CD -_: 312_CD ;_: Figures_NNS 1_CD and_CC 2_LS )_) was_VBD mutated_VBN to_TO SSVA_NNP
          using_VBG forward_RB and_CC reverse_VB primers_NNS with_IN the_DT following_VBG
          sequences_NNS (_( the_DT bases_NNS introducing_VBG the_DT mutation_NN are_VBP
          underlined_VBD )_) ,_, which_WDT also_RB introduced_VBD a_DT new_JJ restriction_NN
          site_NN :_: GAACTGGAGGAGAGTAGC_NNP 
          GTGGCT_NNP GAGAACCGGCGCAGGAGGC_NNP and_CC
          GCCTCCTGCGCCGGTTCTC_NNP 
          AGCCAC_NNP GCTACTCTCCTCCAGTTC_NNP ,_,
          respectively_RB ._. To_TO screen_VB for_IN the_DT presence_NN of_IN the_DT mutation_NN ,_,
          the_DT alpha-_NN 2_CD adrenergic_JJ receptor_NN insert_NN was_VBD cut_VBN from_IN the_DT
          vector_NN using_VBG Hind_NNP III_NNP (_( 895_CD )_) and_CC EcoR_NNP 1_CD (_( 1841_CD )_) and_CC cut_VB with_IN
          Ddel_NNP ._. In_IN a_DT similar_JJ manner_NN a_DT further_JJ AAVA_NNP mutation_NN was_VBD
          prepared_VBN from_IN SSVA_NNP using_VBG GACATCGAACTGGAGGAG_NNP 
          GCCGCA_NNP GTGGCTGAGAACCGGCGC_NNP and_CC
          GCGCCGGTTCTCAGCCAC_NNP 
          TGCGGCC_NNP TCCTCCAGTTCGATGTC_NNP
          forward_RB and_CC reverse_VB primers_NNS ,_, respectively_RB ._. The_DT presence_NN
          of_IN the_DT second_JJ mutation_NN was_VBD determined_VBN using_VBG the_DT AlwNi_NNP ._. To_TO
          further_VB confirm_VB the_DT sequence_NN ,_, the_DT entire_JJ cDNA_NN for_IN the_DT
          insert_NN was_VBD sequenced_JJ for_IN each_DT mutation_NN ._.
        
        
          Cell_NNP culture_NN
          CHO-K_NNP 1_CD cells_NNS (_( American_NNP Type_NNP Culture_NNP Collection_NNP )_) were_VBD
          maintained_VBN in_IN Ham_NNP 's_POS F-_NNP 12_CD medium_NN (_( GIBCO_NNP )_) with_IN 10_CD %_NN fetal_JJ
          bovine_JJ serum_NN (_( GIBCO_NNP 26140_CD -_: 079_CD )_) in_IN 95_CD %_NN air_NN /_NN 5_CD %_NN CO_NNP 
          2_CD at_IN 37_CD °_NN C_NNP in_IN a_DT humid_JJ atmosphere_NN ._.
          Wild-type_NNP and_CC mutated_VBN receptors_NNS in_IN the_DT pRc_NN /_NN CMW_NNP vector_NN
          were_VBD transfected_JJ into_IN CHO-K_NNP 1_CD cells_NNS using_VBG calcium_NN
          phosphate_NN precipitation_NN technique_NN as_IN described_VBN previously_RB
          [_NN 21_CD ]_NN ._. Stable_NNP transfectants_NNS were_VBD selected_VBN with_IN 500_CD
          μg_NN /_NN ml_NN G-_NNP 418_CD (_( Geneticin_NNP ;_: Life_NNP Technologies_NNPS )_) and_CC screened_VBD
          by_IN intact_JJ cell_NN binding_JJ using_VBG [_NN 3_CD H_NNP ]_NN rauwolscine_NN as_RB
          previously_RB described_VBD [_NN 21_CD ]_NN ._.
        
        
          Down-regulation_NNP assays_NNS
          The_DT cells_NNS were_VBD plated_JJ at_IN a_DT density_NN of_IN 2_CD ×_NN 10_CD 5_CD cells_NNS /_NN ml_NN
          in_IN 150_CD -_: mm_NN culture_NN dishes_NNS with_IN 20_CD ml_NN of_IN growth_NN media_NNS and_CC
          allowed_VBN to_TO grow_VB for_IN four_CD days_NNS to_TO near_IN confluence_NN ._. The_DT
          medium_NN was_VBD replaced_VBN with_IN fresh_JJ medium_NN lacking_VBG G-_NNP 418_CD ._.
          Twenty-four_CD hours_NNS later_RB ,_, either_CC 2_CD μl_NN of_IN 3_CD mM_NN
          norepinephrine_NN in_IN 5_CD mM_NN HCl_NNP or_CC just_RB 2_CD μl_NN of_IN 5_CD mM_NN HCl_NNP
          (_( vehicle_NN control_NN )_) was_VBD added_VBN to_TO each_DT of_IN the_DT plates_NNS ._. Cells_NNP
          were_VBD harvested_VBN 24_CD h_NN after_IN adding_VBG norepinephrine_NN or_CC
          vehicle_NN ._. The_DT medium_NN was_VBD removed_VBN and_CC the_DT cells_NNS were_VBD rinsed_JJ
          with_IN 10_CD ml_NN of_IN cold_JJ phosphate-buffered_JJ saline_NN (_( PBS_NNP )_)
          containing_VBG 5_CD mM_NN EGTA_NNP ,_, pH_NN 7_CD ._. 4_CD ._. Another_DT 10_CD ml_NN of_IN PBS_NNP was_VBD
          added_VBN to_TO the_DT plate_NN and_CC the_DT cells_NNS were_VBD scraped_JJ off_IN the_DT
          plate_NN using_VBG a_DT rubber_NN policeman_NN ._. The_DT plate_NN was_VBD rinsed_JJ once_RB
          with_IN 10_CD ml_NN of_IN PBS_NNP ._. The_DT scraped_JJ cells_NNS were_VBD centrifuged_JJ at_IN
          2000_CD ×_NN g_SYM for_IN 5_CD min_NN at_IN 4_CD °_NN C_NNP ,_, the_DT supernatant_NN was_VBD discarded_VBN ,_,
          and_CC the_DT pellet_NN was_VBD stored_VBN at_IN -_: 80_CD °_NN C_NNP until_IN assayed_JJ ._. We_PRP used_VBD
          300_CD nM_NN norepinephrine_NN in_IN the_DT down-regulation_JJ studies_NNS
          because_IN we_PRP have_VBP previously_RB shown_VBN that_IN this_DT concentration_NN
          induces_VBZ maximal_NN down-regulation_JJ for_IN the_DT wild-type_JJ
          alpha-_NN 2_CD C_NNP subtype_NN [_NN 20_CD 24_CD ]_NN ._.
        
        
          Radioligand_NNP Binding_NNP
          Pellets_NNP were_VBD homogenized_JJ in_IN 12_CD ml_NN of_IN ice-cold_JJ 50_CD mM_NN
          Tris_NNP HCl_NNP buffer_NN (_( pH_NN 8_CD ._. 0_CD )_) with_IN a_DT Tissumizer_NNP (_( Tekmar_NNP ,_,
          Cincinnati_NNP ,_, OH_NNP )_) for_IN 20_CD sec_NN at_IN 75_CD %_NN of_IN the_DT maximum_NN speed_NN
          and_CC the_DT suspension_NN was_VBD centrifuged_JJ at_IN 47_CD ,_, 000_CD ×_NN g_SYM for_IN 10_CD
          min_NN at_IN 4_CD °_NN C_NNP ._. This_DT step_NN was_VBD repeated_VBN a_DT second_JJ time_NN ._. For_IN
          saturation_NN experiments_NNS ,_, the_DT resulting_VBG pellet_NN (_( a_DT crude_NN
          particulate_NN membrane_NN fraction_NN )_) was_VBD resuspended_JJ in_IN 200_CD
          volumes_NNS of_IN 25_CD mM_NN NaPO_NNP 
          4_CD buffer_NN (_( pH_NN 7_CD ._. 4_LS )_) and_CC re-homogenized_JJ
          for_IN use_NN in_IN the_DT radioligand_NN binding_JJ assay_NN ._. For_IN
          down-regulation_JJ experiments_NNS the_DT cells_NNS were_VBD re-homogenized_JJ
          in_IN 5_CD ml_NN of_IN 25_CD mM_NN NaPO_NNP 
          4_CD buffer_NN (_( pH_NN 7_CD ._. 4_LS )_) ._.
          For_IN saturation_NN experiments_NNS ,_, duplicate_VB tubes_NNS were_VBD
          prepared_VBN containing_VBG 970_CD μl_NN of_IN tissue_NN and_CC 20_CD μl_NN of_IN [_NN
          3_CD H_NNP ]_NN rauwolscine_NN at_IN six_CD concentrations_NNS ,_, with_IN final_JJ
          concentrations_NNS from_IN approximately_RB 6_CD pM_NN to_TO 0_CD ._. 6_CD nM_NN ._.
          Nonspecific_NNP binding_JJ was_VBD determined_VBN using_VBG a_DT final_JJ
          concentration_NN of_IN 200_CD μM_NN (_( -_: )_) -_: norepinephrine_NN ._. For_IN
          competition_NN experiments_NNS ,_, duplicate_VB tubes_NNS were_VBD prepared_VBN
          containing_VBG 970_CD μl_NN of_IN tissue_NN ,_, 10_CD μl_NN of_IN norepinephrine_NN at_IN
          various_JJ concentrations_NNS ,_, and_CC 20_CD μl_NN of_IN [_NN 3_CD H_NNP ]_NN rauwolscine_NN
          (_( 81_CD ._. 5_LS Ci_NNP /_NN mmol_NN ,_, NEN-Dupont_NNP ,_, Boston_NNP ,_, MA_NNP )_) at_IN a_DT single_JJ
          concentration_NN of_IN 0_CD ._. 12_CD nM_NN ,_, which_WDT is_VBZ approximately_RB the_DT K_NNP 
          d_SYM value_NN ._. Twelve_CD appropriately_RB spaced_JJ
          concentrations_NNS of_IN norepinephrine_NN were_VBD used_VBN in_IN each_DT
          competition_NN experiment_NN ._. The_DT extent_NN of_IN down-regulation_JJ was_VBD
          determined_VBN using_VBG a_DT single_JJ concentration_NN of_IN [_NN
          3_CD H_NNP ]_NN rauwolscine_NN (_( 0_CD ._. 40_CD nM_NN ;_: about_IN 3_CD times_NNS the_DT K_NNP 
          d_SYM value_NN )_) ._. We_PRP have_VBP previously_RB shown_VBN
          that_DT norepinephrine_NN pretreatment_NN does_VBZ not_RB alter_VB the_DT
          radioligand_NN K_NNP 
          d_SYM of_IN the_DT opossum_NN alpha-_NN 2_CD C_NNP adrenergic_JJ
          receptor_NN [_NN 20_CD 24_CD ]_NN ,_, thus_RB making_VBG it_PRP possible_JJ to_TO estimate_VB
          the_DT receptor_NN density_NN with_IN a_DT single_JJ concentration_NN of_IN
          radioligand_NN ._. Total_JJ binding_JJ was_VBD determined_VBN in_IN triplicate_NN
          and_CC nonspecific_JJ binding_JJ in_IN duplicate_VB for_IN each_DT of_IN the_DT
          three_CD dishes_NNS for_IN each_DT condition_NN ._. All_DT assays_NNS were_VBD
          incubated_JJ at_IN room_NN temperature_NN for_IN 60_CD min_NN ._. Membrane_NNP
          suspensions_NNS were_VBD filtered_VBN through_IN Whatman_NNP GF_NNP /_NN B_NNP glass_NN
          fiber_NN filters_NNS with_IN a_DT 48_CD -_: sample_NN Brandel_NNP cell_NN harvester_NN
          (_( Biomedical_NNP Research_NNP and_CC Development_NNP ,_, Gaithersburg_NNP ,_, MD_NNP )_) ._.
          Filters_NNP and_CC tubes_NNS were_VBD washed_VBN three_CD times_NNS with_IN ice-cold_JJ
          50_CD mM_NN Tris_NNP HCl_NNP buffer_NN (_( pH_NN 8_CD ._. 0_CD )_) ._. Radioactivity_NNP was_VBD
          determined_VBN by_IN liquid_JJ scintillation_NN photometry_NN ._. Protein_NNP
          concentrations_NNS were_VBD determined_VBN using_VBG the_DT Bio-_NNP Rad_NNP Protein_NNP
          Assay_NNP (_( Bio-_NNP Rad_NNP ,_, CA_NNP )_) based_VBN on_IN the_DT Bradford_NNP method_NN [_NN 29_CD ]_NN ,_,
          with_IN bovine_JJ serum_NN albumin_NN as_IN the_DT standard_NN ._.
        
        
          Data_NNP analysis_NN
          B_NN 
          max_NN (_( receptor_NN density_NN )_) and_CC K_NNP 
          d_SYM (_( radioligand_NN affinity_NN )_) values_NNS were_VBD
          determined_VBN from_IN the_DT analyses_NNS of_IN saturation_NN experiments_NNS
          utilizing_VBG nonlinear_NN regression_NN with_IN Prism_NNP 3_CD (_( GraphPad_NNP ,_,
          San_NNP Diego_NNP ,_, CA_NNP )_) ._. B_NN 
          max_NN and_CC K_NNP 
          d_SYM values_NNS are_VBP given_VBN as_IN arithmetic_NN and_CC
          geometric_JJ means_NNS ,_, respectively_RB ._. Competition_NN binding_JJ data_NNS
          were_VBD also_RB analyzed_VBN with_IN Prism_NNP 3_CD to_TO determine_VB the_DT IC_NNP 
          50_CD values_NNS based_VBN on_IN the_DT single-site_JJ
          model_NN and_CC slope_NN based_VBN on_IN the_DT variable_JJ slope_NN model_NN ._. K_NNP 
          i_NNP values_NNS were_VBD calculated_VBN from_IN the_DT IC_NNP 
          50_CD values_NNS [_NN 30_CD ]_NN ,_, and_CC are_VBP presented_VBN
          as_IN geometric_JJ means_NNS ._. The_DT statistical_JJ analysis_NN of_IN the_DT
          down-regulation_JJ data_NN was_VBD conducted_VBN using_VBG a_DT two-tailed_JJ
          paired_VBN t-test_JJ of_IN the_DT mean_NN of_IN the_DT duplicate_VB assays_NNS for_IN
          each_DT dish_NN of_IN cells_NNS incubated_JJ in_IN the_DT presence_NN of_IN
          norepinephrine_NN as_IN compared_VBN to_TO control_VB cells_NNS ._.
        
      
    
  
